H-KVLEYVIKV^-OH

Ref. 3D-PP45260

Informations sur le produit

• Nom: H-KVLEYVIKV^-OH
• Synonymes: NH2-Lys-Val-Leu-Glu-Tyr-Val-Ile-Lys-Val^-OH

Description

Peptide H-KVLEYVIKV^-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using H-KVLEYVIKV^-OH include the following: Identification of Two Novel HLA-A∗0201-Restricted CTL Epitopes Derived from MAGE-A4 ZC Jia, B Ni, ZM Huang, Y Tian, J Tang - Journal of , 2010 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/full/10.1155/2010/567594 Evaluation of antitumor immunity efficacy of epitope-based vaccine with B16 cell line coexpressing HLA-A2/H-2kb and CTL multiepitope in HLA transgenic mice S Song, F Wang, X He, Y He, D Li, S Sun - Vaccine, 2007 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0264410X06013600 A MAGE-A1 HLA-A* 0201 epitope identified by mass spectrometry S Pascolo, M Schirle , B Gückel, T Dumrese, S Stumm - Cancer Research, 2001 - AACRhttps://aacrjournals.org/cancerres/article-abstract/61/10/4072/507436 A MAGE-1 antigenic peptide recognized by human cytolytic T lymphocytes on HLA-A2 tumor cells S Ottaviani, Y Zhang , T Boon - Cancer Immunology , 2005 - Springerhttps://link.springer.com/article/10.1007/s00262-005-0705-2 PeptiCHIP: a microfluidic platform for tumor antigen landscape identification S Feola, M Haapala , K Peltonen, C Capasso - ACS , 2021 - ACS Publicationshttps://pubs.acs.org/doi/abs/10.1021/acsnano.1c04371 PeptiCHIP: a novel microfluidic-based chip platform for tumour antigen landscape identification S Feola, M Haapala , K Peltonen, C Capasso, B Martins - 2021 - researchsquare.comhttps://www.researchsquare.com/article/rs-156531/latest Molecular mimicry and cancer vaccine development M Tagliamonte , B Cavalluzzo, A Mauriello, C Ragone - Molecular Cancer, 2023 - Springerhttps://link.springer.com/article/10.1186/s12943-023-01776-0 An innovative approach for HLA typing, molecular tumor testing and the validation of tumor exclusive antigens M Ghosh, L Bichmann, J Scheid, G Guler, H Schuster - bioRxiv, 2020 - biorxiv.orghttps://www.biorxiv.org/content/10.1101/2020.06.05.136754.abstract 225 Optimal-affinity MAGE-A1-specific T cell receptors (TCRs) generated using the humanized TCR-transgenic mouse platform HuTCR are superior to human donor I Gavvovidis, M Leisegang - Journal for , 2021 - search.proquest.comhttps://search.proquest.com/openview/9fa995bc99604cab6fe8e913be377d2f/1?pq-origsite=gscholar&cbl=2040222 Generation of a HuTCR mouse platform-derived MAGE-A1-directed high-affinity TCR with superior potency versus human-derived TCRs. I Gavvovidis, M Leisegang, J Oduro, M Obenaus, E Leo - 2021 - ascopubs.orghttps://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.e14515 Avidity optimization of a MAGE-A1-specific TCR with somatic hypermutation D Bassan, YM Gozlan, A Sharbi-Yunger - European journal of , 2021 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/eji.202049007 Molecular mimicry of SARS-COV-2 antigens as a possible natural anti-cancer preventive immunization C Ragone, A Mauriello, B Cavalluzzo - Frontiers in , 2024 - frontiersin.orghttps://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1398002/abstract

• Marque: Biosynth